Cooley’s 2022 Life Sciences M&A Year in Review
Cooley M&A
JANUARY 25, 2023
Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company. In response to calls from the White House, the FTC also is going beyond traditional enforcement and exploring entirely new approaches to enforcement in the life sciences industry.
Let's personalize your content